NMRA
NASD Neumora Therapeutics, Inc.$0.6776 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.6776, $0.0388 below the day’s high of $0.7164
- YTD change
- -62.15%
- vs 20-day SMA
- -31.17%
- vs 200-day SMA
- -65.36%
Price ranges
Price & Performance
-1.25 (-64.89%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.8% away from all-time highs of $21.0000
- NMRA is down 62% since the beginning of the year
- NMRA is down 62% over the past 12 months
- NMRA is down 51% over the past 1 month
- 5% of all NMRA investors are betting against NMRA
NMRA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -62.8%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0166
- Last 5 days
- -2.05%
- vs 8-day SMA
- -5.79%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The firm offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. It focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.